Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Oisquercq – page 98

1 851 clinical trials in Oisquercq, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Oisquercq at a glance
1 851
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 851 trials in Oisquercq

Open in trial search

Giant cell arteritis

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Prednisolone in Patients with Giant Cell Arteritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Study on Long-Term Safety and Effectiveness of Liposomal Ciclosporin A for Patients with Bronchiolitis Obliterans Syndrome After Lung Transplantation

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin A
  • Sponsor:Zambon S.p.A.

Study on Emicizumab for Patients with Mild or Moderate Hemophilia A Without FVIII Inhibitors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study on 68Ga-NOTA-Anti-HER2 VHH1 for Cancer Patients with Brain Metastasis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:68GANOTA-anti-HER2 VHH1
  • Sponsor:UZ Brussel

Study Comparing the Effectiveness and Safety of Macitentan 75 mg and 10 mg for Patients with Pulmonary Arterial Hypertension

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Macitentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

Study Comparing XL092 and Atezolizumab with Regorafenib for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Exelixis Inc.

Long-Term Follow-Up Study of TX200-TR101 for Patients with Kidney Transplant Rejection

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:TX200-TR101
  • Sponsor:Sangamo Therapeutics Inc.

Fallopian tube cancer+2

Not recruiting

Study of Relacorilant and Nab-Paclitaxel for Patients with Advanced, Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Relacorilant
  • Sponsor:Corcept Therapeutics Inc.

Study of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on the Safety and Effectiveness of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Oisquercq

What the registry says about research in the country

01 Infectious Disease Research

Clinical investigations focusing on recurrent orofacial herpes infections, evaluating innovative therapeutic approaches for patients experiencing frequent outbreaks.

  • Herpes Management
  • Outbreak Prevention
  • Treatment Efficacy

The study aims to assess a new therapeutic intervention for reducing the frequency of herpes episodes through a controlled, double-blind methodology.

02 Viral Disease Control

Research examining the effectiveness of preventive treatments for patients who experience six or more herpes episodes annually.

  • Viral Suppression
  • Long-term Management
  • Quality of Life Impact

The trial evaluates treatment outcomes over a 12-month period, focusing on reducing infection recurrence rates.

03 Clinical Therapeutics

Investigation of placebo-controlled interventions designed to address recurring viral infections affecting the orofacial region.

  • Treatment Innovation
  • Symptom Control
  • Patient Response

This research emphasizes the development of effective strategies for managing frequent herpes outbreaks.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.